Report: Payers may want more biosimilar data

Payers may be more demanding about biosimilars data than regulators prove to be, a report from Decision Resources says. Apparently, payers are questioning whether the FDA's requirements will answer all of their questions about bioequivalence of branded biotech meds and other companies' copycat versions. Report

Suggested Articles

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…